NRx Pharmaceuticals Inc. (NASDAQ:NRXP) saw a downside of -2.46% to $0.34 after subtracting -$0.01 on Monday. The 5-day average trading volume is 427,561 shares of the company’s common stock. It has gained $0.4000 in the past week and touched a new high 1 time within the past 5 days. An average of 435,915 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 476,906.
NRXP’s 1-month performance is -25.62% or -$0.0995 on its low of $0.3400 reached on 08/07/23. The company’s shares have touched a 52-week low of $0.35 and high of $1.54, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, NRXP has lost -69.27% or -$0.7509 and has reached a new high 4 times. However, the current price is down -77.85% from the 52-week high price.
Insider Transactions
NRXP stock investors last saw insider trading activity on Dec 16.Javitt Jonathan C (Director) most recently sold 400,000 shares at $1.00 per share on Dec 07. This transaction cost the insider $400,000. 10% Owner, Javitt Daniel C., sold 8,441 shares at a price of $1.50 on Nov 30. Then, on Nov 29, 10% Owner Javitt Daniel C. sold 13,730 shares at a price of $1.50 per share. This transaction amounted to $20,651.
Valuation Metrics
NRXP stock has a beta of 0.83.
NRx Pharmaceuticals Inc.’s quick ratio for the period ended March 30 was 1.00, with the current ratio over the same period at 1.00.
Earnings Surprise
For the quarterly period ending March 30 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -21.83% to -$11.04 million, while revenue of -$10.24 million was 7.25% off the previous quarter. Analysts expected NRXP to announce -$0.14 per share in earnings in its latest quarter, but it posted -$0.16, representing a -14.30% surprise. EBITDA for the quarter stood at more than -$9.43 million. NRXP stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 22.06 million, with total debt at $12.19 million. Shareholders hold equity totaling $70.31 million.
Let’s look briefly at NRx Pharmaceuticals Inc. (NRXP) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 38.20% to suggest the stock is trending Neutral, with historical volatility in this time period at 77.14%.
The stock’s 5-day moving average is $0.3724, reflecting a -7.95% or -$0.0310 change from its current price. NRXP is currently trading -21.93% above its 20-day SMA, -48.26% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -46.40% and SMA200 by-53.48%.
Stochastic %K and %D was 14.53% and 22.77% and the average true range (ATR) pointed at 0.0335. The RSI (14) points at 37.74%, while the 14-day stochastic is at 17.62% with the period’s ATR at 0.0370. The stock’s 9-day MACD Oscillator is pointing at -0.0096 and -0.0192 on the 14-day charts.
Analyst Ratings
Analysts offering their rating for NRXP stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate NRXP as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 3 have offered a “buy” rating.
What is NRXP’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $2.00 and a high of $9.00, with their median price target at $5.00. Looking at these predictions, the average price target given by analysts is for NRx Pharmaceuticals Inc. (NRXP) stock is $5.33.
